Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Cost Effective Benefits Of New First Step Infertility Treatment Continue; The Conceivex Conception Kit At-Home System Is FDA Cleared Alternative

Posted on: 07 Sep 16

Cost Effective Benefits Of New "First Step" Infertility Treatment Continue

The Conceivex Conception Kit At-Home System Is FDA Cleared Alternative


Bloomfield Hills, Mich. – September 7, 2016 – Despite the recent findings that enrollment in the Affordable Care Act’s (ACA) insurance exchanges has fallen, Conceivex said today that couples across the country continue to be able to take advantage of a new, insurance-covered “first step” therapy to overcome infertility.


The Conception Kit® at-home system is an FDA cleared, drug- and hormone-free treatment for infertility, which couples use at home, and is available for a $30-$75 co-pay (under many insurance plans) with a prescription at more than 65,000 pharmacies in the U.S., including Walmart, Target, Walgreens, and Rite Aid. About 60 percent of insured individuals in the U.S. already have reimbursable access through their pharma benefits manager, including Express Scripts, CVS/Caremark, and others.


The FDA required clinical trials on placement of the Conception Kit’s Conception Cap (a cervical cap used for insemination at home) and instructions by patients. During the trials, 24 percent of the patients got pregnant during the first 30 days.


By comparison, many historic infertility treatment options can prove costly. For example, a single cycle of in-vitro fertilization (IVF) costs $12,500 on average, according to the American Society for Reproductive Medicine, and is not always covered by insurance. And while advancements have been made in IVF treatment, patients who elect this route to address infertility still face risks, including multiple births as well as premature births that can land newborns in the Neonatal Intensive Care Unit (NICU), and thereby drive up overall healthcare costs.


The Conception Kit provides three months of supplies (including 24 ovulation predictors, three pregnancy tests, along with the Conception Cap, and a number of additional proprietary aides) – that, in many cases, would cost more over-the-counter than the total amount of the co-pay – for couples to use in the privacy of their home.


“The Conception Kit represents a new ‘first step’ for couples ahead of IVF and intrauterine insemination (IUI) that can be used at home,” Michael La Vean, President and Founder of Conceivex, maker of the Conception Kit, said. “With more than 20 million women affected by infertility today, and a sizeable population of men facing their own fertility issues, the ACA has given these couples a heretofore unavailable opportunity to start their family inexpensively, more quickly, and privately.”


# # #

About Conceivex, Inc.

Conceivex, Inc., manufactures and distributes the Conception Kit® at-home system, a safe, effective, FDA cleared, and reasonably priced healthcare product that helps couples overcome infertility in the privacy of their own home. The Conception Kit​, which is covered by many insurance plans (including Express Scripts and CVS/Caremark), and is obtainable with a prescription at Walmart, Target, Walgreens, Rite Aid, and 65,000 pharmacies nationwide. Find out more at, on Facebook at, and on LinkedIn (



Media Contact:

Michael W. Robinson

Montgomery Strategies


PA-24 2016

For more information:

Editor's Details

Michael Robinson
The Montgomery Strategies Group

Last updated on: 07/09/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.